2023
Epidemiology and psychiatric correlates of cancer among homeless and unstably housed veterans in the VA healthcare system
Tsai J, Szymkowiak D, Zullig L. Epidemiology and psychiatric correlates of cancer among homeless and unstably housed veterans in the VA healthcare system. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 617-624. PMID: 36791363, DOI: 10.1158/1055-9965.epi-22-1154.Peer-Reviewed Original ResearchConceptsSuicidal ideation/behaviorSubstance use disordersUse disordersVA health care systemVeterans Affairs administrative dataCommon primary siteCancer diagnosisIntrahepatic bile ductsRisk of cancerVA healthcare systemAlcohol use disorderCorrelates of cancerTypes of cancerHealth care systemIncident cancerTreatment of cancerBile ductIncidence rateHigh prevalenceLower riskPsychiatric correlatesPsychiatric characteristicsPsychiatric disordersPrimary sitePsychiatric conditionsPrevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer
Kroenke K, Lam V, Ruddy K, Pachman D, Herrin J, Rahman P, Griffin J, Cheville A. Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer. Journal Of Pain And Symptom Management 2023, 65: 367-377. PMID: 36738867, PMCID: PMC10106386, DOI: 10.1016/j.jpainsymman.2023.01.020.Peer-Reviewed Original ResearchConceptsProportion of patientsRelevant symptomsPatient characteristicsCancer typesNumeric rating scaleComposite scoreMost sociodemographic characteristicsSymptom Management ModelTypes of cancerDistribution-based methodsSymptom burdenClinical symptomsSymptom prevalenceClinical trialsHigh prevalenceMID estimatesPatientsClinical approachSociodemographic characteristicsSymptom dataSymptomsOncology encountersPrevalenceRating ScaleGood internal reliability
2022
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy.
Micevic G, Bosenberg M, Yan Q. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy. Clinical Cancer Research 2022, 29: 1173-1182. PMID: 36449280, PMCID: PMC10073242, DOI: 10.1158/1078-0432.ccr-22-0784.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsImmune checkpoint therapyT cell exhaustionCheckpoint therapyAntitumor immune responseT cell populationsCell-intrinsic immunityTypes of cancerViral mimicry responseLow response rateCheckpoint inhibitorsCurrent immunotherapiesPancreatic cancerSustained responsePreclinical modelsTreatment outcomesImmune responseEndogenous antigensResponse rateTumor typesMultiple epigenetic regulatorsCritical mediatorLow immunogenicityTherapyCancerUsing Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular Carcinoma
Choi DT, Sada YH, Sansgiry S, Kaplan DE, Taddei TH, Aguilar JK, Strayhorn M, Hernaez R, Davila JA. Using Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular Carcinoma. Journal Of Gastrointestinal Cancer 2022, 54: 623-631. PMID: 35773376, PMCID: PMC9247952, DOI: 10.1007/s12029-022-00844-w.Peer-Reviewed Original ResearchConceptsVA Medical CenterHepatocellular carcinomaTreatment recommendationsPerson visitsPatient's perspectiveTumor board recommendationsTumor board reviewCancer care deliveryUse of telemedicineDelivery of careTypes of cancerMTB recommendationsTelemedicine visitsTelemedicine interventionsTreatment referralMedical CenterSemi-structured qualitative interviewsPatientsPilot interventionCare deliveryPatient communicationCancer informationPilot studyAcceptable alternativeIntervention developmentExercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, Irwin ML, Late M, Mansfield S, Marshall TF, Meyerhardt JA, Thomson CA, Wood WA, Alfano CM. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. Journal Of Clinical Oncology 2022, 40: 2491-2507. PMID: 35576506, DOI: 10.1200/jco.22.00687.Peer-Reviewed Original ResearchConceptsWeight loss interventionCancer treatmentSystematic reviewNeutropenic dietPreoperative exerciseLoss interventionActive treatmentResistance exerciseLung cancerWeight managementActive cancer treatmentIntentional weight lossPatient-reported outcomesRisk of infectionQuality of lifeTypes of cancerCurative intentASCO guidelinesHospital stayPostoperative lengthTreatment toxicityOncology providersAdvanced cancerCochrane LibraryCardiorespiratory fitnessAdvanced Glycation End Products-Mediated Oxidative Stress and Regulated Cell Death Signaling in Cancer
Pathak C, Vaidya F, Waghela B, Chhipa A, Tiwari B, Ranjan K. Advanced Glycation End Products-Mediated Oxidative Stress and Regulated Cell Death Signaling in Cancer. 2022, 535-550. DOI: 10.1007/978-981-15-9411-3_44.ChaptersRegulated cell deathCell deathDanger-associated molecular patternsOxidative stressTranscription factorsMolecular mechanismsCancer progressionCellular dysfunctionMolecular patternsRedox imbalanceCancer cellsPathological consequencesTypes of cancerROS generationCurrent understandingAGEs/RAGENucleic acidsAdvanced glycation end productsEnd productsGlycation of proteinsRAGE interactionAccumulationPathophysiological effectsGenesGlycation end productsGlobal assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmInterferon regulatory factor 8Myeloid sarcomaDifferential diagnosisPlasmacytoid dendritic cell neoplasmDesmoplastic small round cell tumorSmall round cell tumorTriple-negative breast cancerStrong uniform expressionDendritic cell neoplasmBroad differential diagnosisNegative breast cancerRound cell tumorAbsence of CD34IHC expression patternsAcute monocytic leukemiaNovel immunohistochemical markerTypes of cancerRegulatory factor 8Cancer Genome AtlasNovel cancer biomarkersRetrospective studySynovial sarcomaCell tumorsPleomorphic sarcomaDoes Opium Consumption Have Shared Impact on Atherosclerotic Cardiovascular Disease and Cancer?
Masoudkabir F, Malekzadeh R, Yavari N, Zendehdel K, Mani A, Vasheghani-Farahani A, Ignaszewski A, Toma M, Roayaei P, Turk-Adawi K, Sarrafzadegan N. Does Opium Consumption Have Shared Impact on Atherosclerotic Cardiovascular Disease and Cancer? Archives Of Iranian Medicine 2022, 25: 50-63. PMID: 35128912, DOI: 10.34172/aim.2022.08.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseRisk factorsOpium consumptionOpium abuseCardiovascular diseaseRisk of ASCVDLifestyle-related risk factorsASCVD risk factorsInadequate physical activityExcessive alcohol consumptionTypes of cancerKinds of cancersPotential carcinogenic effectsDiabetes mellitusPathophysiologic mechanismsOpium abusersUnhealthy dietPhysical activityCurrent evidenceAlcohol consumptionHeart attackCancerCarcinogenic effectsPoor controlDisease
2021
Immunotherapy Treatment for Triple Negative Breast Cancer
Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 2021, 14: 763. PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.Peer-Reviewed Original ResearchTriple-negative breast cancerImmune related adverse eventsBreast cancerMetastatic settingMetastatic triple-negative breast cancerEarly breast cancer settingImmune checkpoint inhibitor therapyBreast cancer settingCheckpoint inhibitor therapyRelated adverse eventsLocal recurrence rateHigh-risk subtypesNegative breast cancerDevelopment of biomarkersTypes of cancerImmunotherapy useAdverse eventsCheckpoint therapyOverall survivalStandard therapySystemic treatmentInhibitor therapyDismal prognosisImmunotherapy treatmentRecurrence rateCancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers 2021, 13: 3016. PMID: 34208598, PMCID: PMC8233712, DOI: 10.3390/cancers13123016.Peer-Reviewed Original ResearchLiquid biopsyEpigenetic biomarkersSpecific epigenetic alterationsDNA methylation changesTumor microenvironmentDNA promoter methylationCommon clinical practiceHigh-incidence malignancyActionable genetic alterationsCancer drug responseSingle geneEpigenetic eventsDNA methylationGene setsMethylation changesTypes of cancerEpigenetic alterationsPrimary tumorClinical trialsClinical valueCerebrospinal fluidHigh incidenceTissue biopsiesClinical practiceEarly alterationsPD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 2021, 18: 345-362. PMID: 33580222, DOI: 10.1038/s41571-021-00473-5.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsSelection of patientsPD-L1L1 antibodyImmunohistochemistry assaysPD-L1 immunohistochemistry assaysOutcomes of patientsBiomarkers of responseCompanion diagnostic assayTypes of cancerPD-1Clinical outcomesSelection biomarkerProspective comparisonClinical challengeNew therapiesFuture treatmentPatientsSolid tumorsClinical useSpecific agentsInter-assay variabilityBiomarkersCurrent roleDiagnostic assays
2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatientsAGE-RAGE synergy influences programmed cell death signaling to promote cancer
Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. Molecular And Cellular Biochemistry 2020, 476: 585-598. PMID: 33025314, DOI: 10.1007/s11010-020-03928-y.Peer-Reviewed Original ResearchConceptsCell deathCancer cellsCell death machinerySet of genesCellular redox balanceSignal transduction pathwaysCell death pathwaysComplex signaling mechanismsCell survival mechanismAGE-RAGEDeath machineryCellular reprogrammingTransduction pathwaysDeath pathwaysMolecular paradigmRedox balanceSurvival mechanismSignaling mechanismCancer progressionAGE-RAGE signalingPresent review focusProgression of malignancyTypes of cancerUpregulated expressionChronic hyperglycemic conditionsOptimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda D, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 227-241. PMID: 32417409, PMCID: PMC7646202, DOI: 10.1016/j.ijrobp.2020.05.011.Peer-Reviewed Original ResearchConceptsBreast cancerRadiation therapyTiming of RTImmune checkpoint blockadeSystemic immune responsesEffector immune cellsSystemic antitumor effectsBreast radiation oncologistsTypes of cancerCheckpoint blockadeTumor immunogenicityImmune cellsClinical trialsImmune responseSystemic effectsAntitumor effectsTranslational studiesHigh dosesRadiation oncologistsImmunotherapyCancerDistant sitesTherapyFurther explorationOncologistsCancer prognosis with shallow tumor RNA sequencing
Milanez-Almeida P, Martins A, Germain R, Tsang J. Cancer prognosis with shallow tumor RNA sequencing. Nature Medicine 2020, 26: 188-192. PMID: 32042193, DOI: 10.1038/s41591-019-0729-3.Peer-Reviewed Original ResearchConceptsCancer prognosisTumor RNA-seq dataTumor RNA sequencingPrediction of outcomeTypes of cancerClinical outcomesRNA sequencingAdverse outcomesRelative riskDisease outcomeOutcome predictionTumor RNA-seqPersonalized oncologyTranscriptional signatureCancer1–3Molecular pathwaysOutcomesPrognosisLongitudinal analysisTranscriptional pathwaysCancerThe role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
Brown M, Zhang W, Yan D, Kenath R, Le L, Wang H, Delitto D, Ostrov D, Robertson K, Liu C, Pham K. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. PLOS ONE 2020, 15: e0226917. PMID: 31929540, PMCID: PMC6957139, DOI: 10.1371/journal.pone.0226917.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTypes of cancerDuctal adenocarcinomaSurvivin expressionSurvivin inhibitorClinical response rateNovel survivin inhibitorHalf of patientsElevated survivin expressionLower patient survivalPancreatic tumor microenvironmentPotential therapeutic targetExpression of survivinRole of survivinField of oncologyPancreatic cancer linesImmunotherapeutic approachesPatient survivalUntreated cohortTherapeutic responseInhibitor of survivinTreatment resistancePDAC progressionEffective treatmentTumor cell migration
2019
Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation
Cosgun K, Deb G, Yang X, Xiao G, Sadras T, Lee J, Chan L, Kume K, Yang L, Geng H, Chan J, Song J, Jumaa H, Polson A, Clevers H, Müschen M. Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. Blood 2019, 134: 748. DOI: 10.1182/blood-2019-127263.Peer-Reviewed Original ResearchB-cell lineage acute lymphoblastic leukemiaWnt/β-catenin signalingΒ-catenin signalingNuclear β-cateninAntibody-drug conjugatesB cell developmentB cell survivalΒ-cateninB lymphopoiesisFunction of LGR5Median mRNA levelsTime of diagnosisPoor clinical outcomeRole of LGR5Acute lymphoblastic leukemiaB-cell lymphomaLeukemia initiating cellsWnt/β-cateninHigh surface expressionMalignant B-cell transformationCell linesB cell precursorsTypes of cancerHuman colon cancer cell linesB-cell lineageImmunoepidemiology of Cancer
Ma X, Wang R. Immunoepidemiology of Cancer. 2019, 215-224. DOI: 10.1007/978-3-030-25553-4_13.Peer-Reviewed Original ResearchImmune system functionTypes of cancerImmunological factorsCancer immunotherapyTreatment modalitiesChronic diseasesRadiation therapyEpidemiological studiesDrug AdministrationImmunotherapyInfectious diseasesCancerDiseaseExciting new eraSystem functionChemotherapySurgeryImmunoepidemiologyEtiologyTherapyYearsInfectionAdministrationImportant roleThe use of cell free DNA in the diagnosis of HCC
Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Research 2019, 2019: 34. PMID: 31673629, PMCID: PMC6822275, DOI: 10.20517/2394-5079.2019.30.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDiagnosis of HCCHepatocellular carcinomaNon-invasive biomarkersCommon malignant tumorPotential clinical utilityCell-free nucleic acidsTypes of cancerCell-free DNALiquid biopsy analysisAnalysis of bloodLiver biopsyPeripheral bloodTumor recurrenceMalignant tumorsProstate cancerEarly diagnosisClinical utilityBiopsy analysisAdvanced stageHigh mortalityTreatment monitoringLiquid biopsyDiagnosisBody fluidsBiopsy
2018
Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies
Chen Z, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies. Blood 2018, 132: 1587. DOI: 10.1182/blood-2018-99-113674.Peer-Reviewed Original ResearchAutoreactive B-cell antigen receptorsB-cell malignanciesAcute lymphoblastic leukemiaAutoreactive B cellsB cellsCell malignanciesB cell antigen receptorNormal B cellsTypes of cancerAIC activationTargeted therapyAutoreactive clonesMalignant transformationTargeted activationAutoreactive B lymphocytesLymphocyte developmentPI3KB-cell lymphomaB-lymphoid malignanciesB-cell receptor signalingDrug-resistant leukemiaB-cell leukemiaB-cell tumorsCell deathNegative selection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply